Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
Conditions: Non-small Cell Lung Cancer; Cardiac Toxicity Interventions: Other: Impedance cardiography Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer; Camrelizumab Interventions: Drug: Camrelizumab + chemotherapy+Thalidomide; Drug: Camrelizumab + chemotherapy+placebo Sponsors: Tongji University; Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Cadonilimab plus Pemetrexed and Anlotinib Sponsors: Guangzhou University of Traditional Chinese Medicine; Akeso Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations
Berlin, Germany, February 26, 2024– Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Conditions: Non-small Cell Lung Cancer Interventions: Drug: DZD9008 plus Bevacizumab Sponsors: Dizal Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Repositioning Immunotherapy in VetArans With Lung Cancer
Conditions: Non-Small Cell Lung Cancer Interventions: Drug: Nivolumab Sponsors: VA Office of Research and Development Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
BostonGene and Exigent Genomic INsight Study
Conditions: Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Sarcoma Sponsors: BostonGene; Exigent Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression
Conditions: Carcinoma, Non-Small-Cell Lung Interventions: Drug: Toripalimab Sponsors: Ruijin Hospital; Guangdong Provincial People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Oral Microbiome Diagnostics of Lung Cancer
Conditions: Lung Cancer Interventions: Diagnostic Test: NCCN (National Comprehensive Cancer Network) diagnosis Sponsors: TC Erciyes University; THE SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF T ÜRKİYE Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Conditions: Advanced Non-small Cell Lung Cancer Interventions: Drug: REGN2810; Other: Platinum-doublet chemotherapy Sponsors: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Lazertinib+Pemetrexed+Carboplatin; Drug: Lazertinib Sponsors: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Conditions: Non-small Cell Lung Cancer (NSCLC) Interventions: Drug: Atezolizumab; Drug: Tiragolumab; Drug: Placebo Sponsors: Hoffmann-La Roche Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
Conditions: Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage IIIA Interventions: Drug: SB27; Drug: EU sourced Keytruda; Drug: US sourced Keytruda Sponsors: Samsung Bioepis Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer
Conditions: Lung Cancer Interventions: Drug: Sintilimab plus chemotherapy Sponsors: The First Hospital of Jilin University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
Conditions: SCLC,Extensive Stage Interventions: Drug: Adebrelimab Sponsors: Henan Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
